Cited by 1,528

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

The Pharmacology and Management of the Vitamin K Antagonists

Ansell, Jack, Hirsh, Jack, Poller, Leon, Bussey, Henry, Jacobson, Alan, Hylek, Elaine·2004·Chest

DOI 10.1378/chest.126.3_suppl.204s

Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1378/chest.126.3_suppl.204s

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Systematic overview of warfarin and its drug and food interactions
Holbrook, A. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1095 · Cited by 1,160
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome
Crowther, M. A., Ginsberg, J. S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035241 · Cited by 919
Self-citation
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., Moll, S., Kessler, C. M., Elliott, C. G., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035029 · Cited by 808
Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients
Rosove, M. H., & Brewer, P. M. C. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-4-303 · Cited by 700
A randomized clinical trial of high‐intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
FINAZZI, G., MARCHIOLI, R., BRANCACCIO, V., SCHINCO, P., WISLOFF, F., MUSIAL, J., BAUDO, F., BERRETTINI, M., Testa, S., D'ANGELO, A., et al. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01340.x · Cited by 585
Department of Veterans Affairs Cooperative Studies Program Clinical Trial Comparing Combined Warfarin and Aspirin With Aspirin Alone in Survivors of Acute Myocardial Infarction: Primary Results of the CHAMP Study
Fiore, L. D., Ezekowitz, M. D., Brophy, M. T., Lu, D., Sacco, J., & Peduzzi, P. (2002) · Circulation · doi:10.1161/hc0502.103329 · Cited by 224
Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial
Matchar, D. B., Samsa, G. P., Cohen, S. J., Oddone, E. Z., & Jurgelski, A. E. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01131-2 · Cited by 141
Bleeding and re-thrombosis in primary antiphospholipid syndrome on oral anticoagulation: An 8-year longitudinal comparison with mitral valve replacement and inherited thrombophilia
Ciampa, A., Margaglione, M., Scenna, G., Iannaccone, L., Brancaccio, V., & Ames, P. R. J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-11-0723 · Cited by 49

Show all 10 references

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Anticoagulation Control and Prediction of Adverse Events in Patients With Atrial Fibrillation: A Systematic Review
Wan, Y., Heneghan, C., Perera, R., Roberts, N., Hollowell, J., Glasziou, P., Bankhead, C., & Xu, Y. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.796185 · Cited by 514
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000184955.08453.a8 · Cited by 376
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study
Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., & Segers, A. (2008) · Blood · doi:10.1182/blood-2008-05-160143 · Cited by 342
The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation
Themistoclakis, S., Corrado, A., Marchlinski, F. E., Jais, P., Zado, E., Rossillo, A., Di Biase, L., Schweikert, R. A., Saliba, W. I., Horton, R., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.11.039 · Cited by 276
Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
BULLER, H., DEITCHMAN, D., PRINS, M., & SEGERS, A. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03054.x · Cited by 252
The Cardiovascular Research Network: A New Paradigm for Cardiovascular Quality and Outcomes Research
Go, A. S., Magid, D. J., Wells, B., Sung, S. H., Cassidy-Bushrow, A. E., Greenlee, R. T., Langer, R. D., Lieu, T. A., Margolis, K. L., Masoudi, F. A., et al. (2008) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.801654 · Cited by 137
Does POCT reduce the risk of error in laboratory testing?
Plebani, M. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.03.014 · Cited by 97
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing
Meckley, L. M., Gudgeon, J. M., Anderson, J. L., Williams, M. S., & Veenstra, D. L. (2010) · PharmacoEconomics · doi:10.2165/11318240-000000000-00000 · Cited by 97
Thrombin‐inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis
MYERSON, J., HE, L., LANZA, G., TOLLEFSEN, D., & WICKLINE, S. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04339.x · Cited by 96
Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian Men
Soon, D., Kothare, P. A., Linnebjerg, H., Park, S., Yuen, E., Mace, K. F., & Wise, S. D. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006291622 · Cited by 54

Authors: Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E.
Venue: Chest
Publisher: Elsevier BV
Published: 2004-09
Volume: 126
Issue: 3
Pages: 204S-233S
ISSN: 0012-3692 (ISSN-L)
DOI: 10.1378/chest.126.3_suppl.204s
OpenAlex: W2096698984
Cited by: 1,528
References: 10
FWCI: 76.00
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

The Pharmacology and Management of the Vitamin K Antagonists

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

Data sources